Abstract | OBJECTIVE: METHODS: Seventy patients suffering from endometriosis, adenomyoma and fibromyoma were divided into two groups: extended-interval dosing (group E) and conventional dosing (group C). There were treated with injection of triptorelin 3.75 mg intramuscularly either every 6 weeks of totally four dose regimen (group E) or every 4 weeks of six dose regimen (group C). Comparison was made in improvement of symptoms, size of uterus and volume of tumor, as well as in serum levels of 17beta-estradiol, luteinizing hormone, and follicle-stimulating hormone. RESULTS: In each group, symptoms and tumor growth significantly improved after treatment (P < 0.05). For the patients of both groups E and C, the levels of gonadotropins and gonadal steroids were obviously reduced throughout the treatment period and up to 8 - 10 weeks after the injection of the last dose (P < 0.05). The hormonal profile of group E was similar to group C (P > 0.05). CONCLUSIONS:
|
Authors | De-yan Liu, Mei-jiao Gu, Jia-zhen Shu, Yu-xia Shi, Chang-yu Wang, Zhi-qiang Han |
Journal | Zhonghua fu chan ke za zhi
(Zhonghua Fu Chan Ke Za Zhi)
Vol. 41
Issue 10
Pg. 656-9
(Oct 2006)
ISSN: 0529-567X [Print] China |
PMID | 17199917
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Triptorelin Pamoate
|
Topics |
- Adenomyoma
(drug therapy)
- Adult
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Drug Administration Schedule
- Dysmenorrhea
(drug therapy)
- Endometriosis
(drug therapy)
- Female
- Humans
- Treatment Outcome
- Triptorelin Pamoate
(therapeutic use)
- Uterine Neoplasms
(drug therapy)
|